Evidence map›Paper›PMID 27119957›Full record

ReviewDer Urologe. Ausg. A2016

[Focal therapy for small renal masses : Observation, ablation or surgery].

J J Wendler, B Friebe, D Baumunk, A Blana, T Franiel, R Ganzer, B Hadaschik, T Henkel, K U Köhrmann, J Köllermann and 10 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 1 country.

J J WendlerArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland. Johann.wendler@med.ovgu.de.
B FriebeUniversitätsklinik für Radiologie und Nuklearmedizin, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Deutschland.
D BaumunkArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
A BlanaArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
T FranielArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
R GanzerArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
B HadaschikArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
T HenkelArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
K U KöhrmannArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
J KöllermannArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
T KuruArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
S MachtensArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
A RoosenArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
G SalomonArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
H P SchlemmerArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
L SentkerArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
U WitzschArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
U B LiehrArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
J RickeUniversitätsklinik für Radiologie und Nuklearmedizin, Otto-von-Guericke-Universität Magdeburg, Magdeburg, Deutschland.
M SchostakArbeitskreis für fokale und Mikrotherapie der Akademie (AKFM), Deutsche Gesellschaft für Urologie (DGU) e. V., Düsseldorf, Deutschland.
Deutsche Gesellschaft für Urologie · DEOtto-von-Guericke University Magdeburg · DELeipzig University · DESana Klinikum Offenbach · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe rising incidence of renal cell carcinoma, its more frequent early detection (stage T1a) and the increasing prevalence of chronic renal failure with higher morbidity and shorter life expectancy underscore the need for multimodal focal nephron-sparing therapy. DISCUSSION: During the past decade, the gold standard shifted from radical to partial nephrectomy. Depending on the surgeon's experience, the patient's constitution and the tumor's location, the intervention can be performed laparoscopically with the corresponding advantages of lower invasiveness. A treatment alternative can be advantageous for selected patients with high morbidity and/or an increased risk of complications associated with anesthesia or surgery. Corresponding risk stratification necessitates previous confirmation of the small renal mass (cT1a) by histological examination of biopsy samples. Active surveillance represents a controlled delay in the initiation of treatment.

resultsPercutaneous radiofrequency ablation (RFA) and laparoscopic cryoablation are currently the most common treatment alternatives, although there are limitations particularly for renal tumors located centrally near the hilum. More recent ablation procedures such as high intensity focused ultrasound (HIFU), irreversible electroporation, microwave ablation, percutaneous stereotactic ablative radiotherapy and high-dose brachytherapy have high potential in some cases but are currently regarded as experimental for the treatment of renal cell carcinoma.

Indexed as

Carcinoma, Renal CellCatheter AblationCryosurgeryHumansKidney NeoplasmsLaparoscopyMinimally Invasive Surgical ProceduresNeoplasm StagingNephrectomyOrgan Sparing TreatmentsWatchful WaitingAblationActive surveillanceFocal therapyPartial kidney resectionRenal cell carcinoma

Identifiers

PMID27119957
OpenAlexW2415626179

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.